Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Yanfeng Chen

Internal Medicine Brooklyn, NY Medical Doctor

NPI 1740280171 CMS profile 123873

5517 7Th Ave, 1F, Brooklyn, NY 11220

Open in the dashboard

General payments

$58,591

726 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yanfeng Chen of Brooklyn, NY is reported in the CMS Open Payments database as having received $58,591 across 726 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,301 101
2024 General $12,552 120
2023 General $6,482 92
2022 General $5,972 72
2021 General $7,099 109
2020 General $2,781 79
2019 General $13,403 153

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yanfeng Chen
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Yanfeng Chen were reported at $10,301. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Yanfeng Chen Internal Medicine median Middle half National median
2019 $13,403 $159 $48–$570 $163
2020 $2,781 $119 $33–$402 $114
2021 $7,099 $135 $37–$521 $132
2022 $5,972 $141 $42–$496 $149
2023 $6,482 $149 $45–$519 $160
2024 $12,552 $154 $47–$537 $164
2025 $10,301 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Gilead Sciences, Inc. $36,169 122 payments
  2. AstraZeneca Pharmaceuticals LP $4,691 139 payments
  3. GlaxoSmithKline, LLC. $3,498 56 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $2,189 47 payments
  5. Amgen Inc. $1,930 40 payments
  6. Novo Nordisk Inc $1,586 34 payments
  7. AbbVie, Inc. $1,234 21 payments
  8. Amarin Pharma Inc. $737 42 payments
  9. Lilly USA, LLC $710 23 payments
  10. Merck Sharp & Dohme Corporation $486 28 payments
  11. Other $5,360 174 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $30,770 19 payments
  2. Food and Beverage $25,051 679 payments
  3. Consulting Fee $2,100 1 payment
  4. Travel and Lodging $438 1 payment
  5. Education $231 26 payments
Products named General payments · program years 2019–2025
  1. Vemlidy $24,996 32 payments
  2. FARXIGA $2,093 77 payments
  3. BREZTRI $1,467 34 payments
  4. AREXVY $1,244 10 payments
  5. JARDIANCE Diabetes $768 12 payments
  6. SHINGRIX $735 10 payments
  7. AIRSUPRA $676 14 payments
  8. EVENITY $654 18 payments
  9. Ozempic $648 23 payments
  10. JARDIANCE Diabetes $639 19 payments
  11. Other $15,713 537 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 173 drugs

Part D claims

20,039

Median for Internal Medicine: 777

Drug cost

$2,231,853

Median for Internal Medicine: $73,373

Branded share of claims

24.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vascepa Icosapent Ethyl Brand 865 $358,099
Farxiga Dapagliflozin Propanediol Brand 285 $220,329
Jardiance Empagliflozin Brand 253 $203,797
Vemlidy Tenofovir Alafenamide Brand 133 $189,635
Rybelsus Semaglutide Brand 110 $147,331
Januvia Sitagliptin Phosphate Brand 142 $103,558
Diclofenac Epolamine Generic 149 $98,297
Eliquis Apixaban Brand 115 $89,880
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 102 $64,695
Xarelto Rivaroxaban Brand 82 $61,018

The 10 drugs with the highest cost, of 173 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$67,485

Of which drugs: $2,786

Medicare patients

147

Average age 76

Services billed

1,371

79 women, 68 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Diabetes 44%
Arthritis 37%
Chronic kidney disease 33%
Heart failure 22%
Ischemic heart disease 21%
Osteoporosis 20%
Alzheimer's or dementia 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 23 23 $1,882

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Vemlidy
  • Gilead Sciences, Inc. $3,350
$3,350 133 —
AREXVY
  • GlaxoSmithKline, LLC. $995
$995 25 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $470
  • Lilly USA, LLC $178
$648 253 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $457
$457 102 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $404
$404 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

726 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record